MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Experimental therapeutics"

  • MDS Virtual Congress 2021

    Overcoming clinical research challenges during a pandemic: selection and implementation of digital phenotyping solutions in a natural history study of G2019S LRRK2 Parkinson’s disease.

    N. France, C. Tomkins-Lane, M. Maurer, C. Barlow, E. Davies, C. Matthews, A. Palozoglu, L. Farid (South San Francisco, USA)

    Objective: To identify candidate wearable devices or digital solutions suitable for conducting the Timed Up and Go (TUG) test and evaluate real-world performance remotely during…
  • MDS Virtual Congress 2021

    PHYSICAL ACTIVITY AT HOME IS ABLE TO REDUCE THE WORSENING IN QUALITY OF LIFE IN PARKINSON’S DISEASE DURING COVID-19 PANDEMIC

    I. Nascimento, C. Batista, D. Coelho, L. Almeida, A. Guimarães, A. Lindquist, V. Israel, H. Kanegusuku, R. Guimarães, N. Bosaipo, R. Barbosa, C. Correa, M. Finatto, F. Mendes, R. Azamor, M. Piemonte (São Paulo, Brazil)

    Objective: To compare the effects of physical activity (PA) at home with and without remote supervision on the motor and non-motor aspects of daily life…
  • MDS Virtual Congress 2021

    The PD-1102 trial in advanced Parkinson’s disease: safety and clinical outcomes from a 3-year phase 1b study of AADC gene therapy administered via a posterior approach

    S. Factor, R. Gross, A. van Laar, C. Christine, P. Larson, S. Kostyk, R. Lonser, E. Fine, O. Kwhaja, C. Li, A. Meier, G. Liang, E. Roberts, R. Richardson (Atlanta, USA)

    Objective: To present 3-year safety and clinical outcome data from a phase 1b, open-label trial of VY-AADC01 (NBIb-1817) for Parkinson’s disease (PD) patients with motor…
  • MDS Virtual Congress 2021

    IS THE HYPOXIA EXPOSURE BENEFICIAL FOR PEOPLE WITH PARKINSON’S DISEASE? A SCOPE REVIEW

    C. Kalva-Filho, M. Kuroda, E. Costa, J. Corradini, F. Barbieri (Bauru, Brazil)

    Objective: To explore the current evidence and identify knowledge gaps, we conducted a scoping review about the hypoxia exposure effects on people with Parkinson’s disease…
  • MDS Virtual Congress 2020

    A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AKST4290 in Subjects with Parkinson’s Disease on Stable Dopaminergic Treatment (TEAL Study)

    E. Rawner, J. Powell, S. Minami, K. Tang, V. Klutzaritz, E. McCaskill Newman, J. Hannestad (San Carlos, CA, USA)

    Objective: Assessment of efficacy and safety in subjects with Parkinson’s disease (PD) following treatment for 12 weeks with placebo or AKST4290, a highly specific and…
  • MDS Virtual Congress 2020

    Deep learning approach for Parkinson’s disease classification from facial expressions: A pilot feasibility study

    O. Phokaewvarangkul, P. Vateekul, D. Surangsrirat, R. Bhidayasiri (Bangkok, Thailand)

    Objective: To apply deep learning and traditional machine learning approaches to images of different facial expressions from patients and controls to aid in the prediction…
  • MDS Virtual Congress 2020

    Weeding Through the Haze: A Survey on Cannabis Use Among People with Parkinson’s Disease

    M. Feeney, B. Kluger, A. Stoessl, D. Bega, S. Gilbert, A. Hosang, E. Ogren, K. Schroeder, C. Evers, J. Beck (New York, NY, USA)

    Objective: To identify themes in cannabis use among people with Parkinson’s disease to inform medical recommendations and the design of future clinical trials. Background: Parkinson’s…
  • MDS Virtual Congress 2020

    Pridopidine for the Treatment of Early Huntington’s Disease

    M. Geva, R. Reilmann, C. Olanow, M. Leinonen, Y. Cohen, P. Meyer, A. McGarry, O. Sabri, M. Hayden, K. Kieburtz (Herzliya, Israel)

    Objective: Assess the efficacy of pridopidine 45 mg bid for maintenance of total functional capacity (TFC) and motor function in early HD patients. Background: Pridopidine…
  • MDS Virtual Congress 2020

    Translatable biomarkers in gene therapy for Huntington’s Disease: learnings from pre-clinical studies

    A. Valles, M. Evers, A. Stam, M. Sogorb-Gonzales, C. Brouwers, C. Vendrell, S. Acar-Broekmans, V. Fodale, A. Bresciani, R. Nieuwland, Z. Ellederova, J. Motlik, M. de Haan, B. Leavitt, S. van Deventer, P. Konstantinova (Amsterdam, Netherlands)

    Objective: We have developed AAV5-miHTT, a recombinant AAV-based gene therapy expressing an engineered microRNA that specifically binds to HTT exon1, resulting in lowering of both…
  • MDS Virtual Congress 2020

    Effect of herbal medicine against Parkinson’s Diseases- An in silico studies

    S. Subramani, Y. Gupta, R. Sharma, P. Prasad (Gwalior, India)

    Objective: To evaluate the effect of the bioactive compounds of Gymnema sylvestre on treatment of Parkinson’s diseases. Background: Neurodegenerative diseases, such as Parkinson’s and Alzheimer’s,…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 12
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley